Originally Aired: February 23, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

With gene therapy rapidly shifting from orphan to prevalent indications, the demand for viral vectors is surging—especially for adeno-associated virus (AAV). Yet the industry is still primarily operating on the legacy process of transient transfection, which requires large amounts of expensive GMP-grade DNA while carrying only limited scale-up potential. Nobody would consider such a process for industrial antibody production, but it is still the norm for AAV. The ELEVECTA™ platform of inducible stable AAV producer cell lines solves this issue.

In this GEN webinar, we will dive deeply into the ELEVECTA™ technology to better understand how you can produce high-titer and high-quality AAV vectors as easily as antibodies.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.

cytiva logo

Markus Krieger
Markus Krieger, PhD
VP Technology Development
Cevec Pharmaceuticals GmbH – Now Part of Cytiva